🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Can’t discuss GI cancers on an empty stomach!!😉

It’s always brilliant to see the STAR-TREC phase II data - here expertly presented by Prof Marijnen. Phase III is recruiting very well - with >210 pts randomised in 3 countries to the organ preservation arms #ESTRO2023 #rectalcancer #organpreservation

Couldn’t agree more Michael Chuong. Elective SBRT coverage I think has an important role when treating pancreatic cancer. Quite the opposite thinking than before when it was all about keeping target volumes as small and as tight as possible. Great work!

When in Vienna, Radiation Oncologists go to the Opera! ⁦@florencehuguet⁩ #ESTRO23

Our Invited Article has been published in the #ASCO23 Educational Book. Josh Mailman Karyn Goodman, MD, MS and Dr. Wendy Garrett. Science and Innovation at Cancer Research UK Cancer Grand Challenges Dr. Cathy Eng Kimmie Ng, MD, MPH Manju George MVSc PhD Rectal Cancer Survivor Scott Kopetz Michael Sapienza Kim Newcomer Global Colon Cancer Association Candace Henley ascopubs.org/doi/10.1200/ED…

🚨🚨🚨Early ACT 4 Anal SCC Results!!! 50.4 Gy in 28fx vs 41.4 Gy in 23fx Cape + MMC 🔵 Similar (~90%) 6m complete response 🔵 Less toxicity with de-intensification Looking forward to maturation of LC/PFS! Fantastic news for our patients and congrats to the investigators!!

Patient Advocates and Researchers as Partners in Cancer Research: A Winning Combination ascopubs.org/doi/10.1200/ED… Karyn Goodman, MD, MS Laura D Porter, MD FASCO Josh Mailman Dr. Wendy Garrett #ASCO23 #EdBook

🏆 Excited to share I've been awarded an R50 from National Cancer Institute to support my work in cancer clinical trials at The Tisch Cancer Institute. Grateful for this opportunity to expand access to NCI-sponsored clinical trials to our patients: rb.gy/4he8x

🔖 Our latest research, led by Marina Moskalenko, MD is out in Current Oncology! We found that using fiducial markers in liver SBRT can aid in achieving more accurate and consistent treatment setups. Congrats to the whole team. Read the full study here: mdpi.com/1718-7729/30/5…

Thank you ⁦Katie Couric⁩ for spreading the word about #HPV -related cancers and #vaccines. ⁦⁦Anal Cancer Foundation⁩ ⁦HPV Cancers Alliance⁩ Can Older People Get HPV or the Vaccine? | KCM katiecouric.com/health/hpv-old…

Proud to receive @LustgartenFdn's 2023 LEAD grant for our intervention to increase clinical trial access for Mandarin & Spanish-speaking cancer patients at The Tisch Cancer Institute, Northwell Health & Johns Hopkins University. Your support propels our commitment to inclusive healthcare. Thank you!

Congrats to all of the OPRA investigators and Julio Garcia Aguilar - 5-year data presented today by Floris Verheij Memorial Sloan Kettering Cancer Center ; LCRT --> FOLFOX: higher rates of organ preservation, lower rates of local regrowth AND no decrement in oncologic outcomes ASCO; #ASCO23 ASCRS_1

After the protest by the #radonc community the The New York Times at least scaled down the headline by removing the term "brutal". Also very important is the inclusion of the " could" ( conditional verb), which means that this can only happen under certain conditions ( average risk).

Carmelo Tuscano🇮🇹🇪🇺 The New York Times The American Society for Radiation Oncology (ASTRO) Gastrointestinal Cancers Resource Panel issued the following statement regarding the PROSPECT clinical trial for patients with rectal cancer: astro.org/News-and-Publi…

JUST out! Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer jitc.bmj.com/content/11/6/e… #immunotherapy Society for Immunotherapy of Cancer Kristen Ciombor Van Morris, MD Smitha Krishnamurthi #gicancer #cancer Journal for ImmunoTherapy of Cancer #SITCGuidelines

So great to see this study published - another exciting step toward more personalization of cancer care. Patients have options! RT still key in low rectal tumors for non-operative management. Preoperative Treatment of Locally Advanced Rectal Cancer | NEJM nejm.org/doi/10.1056/NE…

Very proud to be a part of the #NCTN Task Force on Diversity in GI Onology. Thank you Rebecca Snyder for leading this discussion on #DEI in the NCTN. Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership academic.oup.com/jnci/article/d…

Check out our article on appendiceal cancer staging published in @CAonline! AJCC ACS Cancer Programs

Great to be part of this novel approach for patients with pancreatic cancer. Mike Pishvaian - look forward to the presentation at #ESMO23. #PancreaticCancer LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. con... sciencedirect.com/science/articl…

Looking forward to great speakers and important discussions on how to leverage AI and bioinformatics for expanding access to oncology clinical trials at the Ci4CC meeting in La Jolla, Ca